For the first time, the United States approved the Covid test by breathing

According to the concerned, this device is capable of giving accurate results in less than three minutes

This is the first time that the US Food and Drug Administration (FDA) has approved the collection of respiratory samples for emergency coronavirus testing.

The new method claims to be able to detect infections within three minutes and accurately.

“Today’s approval is another example of the rapid innovation of coronavirus diagnostic testing,” Jeff Shuren, director of the FDA’s Center for Devices and Radiological Health, said in a statement Thursday (April 14th).

The “InspectIR Covid-19 Breathalyzer” can be used in environments where patient samples are collected and analyzed simultaneously. Such as- doctor’s office, hospital and mobile testing site.

It is an instrument the size of a portable luggage, and one machine can analyze about 180 samples per day.

Evan Maldonado, an infectious disease specialist at Stanford University School of Medicine, is working on another breathalyzer test. He told the New York Times that having more options for sample testing would help transform the epidemic into a local one. So the more options there are, the easier it will be to learn about the virus.

The effectiveness of the device was verified in a large study of 2,409 people who did not show signs of infection.

The test showed 91.2% sensitivity (percentage of correctly identified positive samples) and 99.3% specificity (percentage of negative samples correctly identified in the test).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

The experiment was compared with a follow-up clinical study focusing on the Omicron variant.

Gas chromatography uses a technique called gas mass-spectrometry (GC-MS) to isolate and identify chemical compounds from the “InspectIR Covid-19 Breathalyzer” Can

The FDA warns that “negative exposure should be considered in light of the patient’s recent exposure, history, and the presence of clinical signs and symptoms consistent with Covid-19, as they do not and should not rule out SARS-Cov-2 infection.”

The manufacturer of the Inspector IR Breathalyzer expects to be able to manufacture about 100 instruments per week.

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button